Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 9/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464499 | 0.84 | NR4A2 (0.34) | GRM5 | |
| SCHEMBL7898244 | 0.81 | KMO (0.38) | — | |
| SCHEMBL427485 | 0.81 | FAAH (0.38) | GRM5 | |
| SCHEMBL427643 | 0.81 | HSD17B1 (0.37) | PIK3R1 | |
| SCHEMBL425743 | 0.81 | FAAH (0.43) | GRM5 | |
| SCHEMBL425899 | 0.80 | CNR2 (0.34) | GRM5RIPK1 | |
| SCHEMBL427956 | 0.79 | TP53 (0.39) | — | |
| SCHEMBL427770 | 0.78 | FYN (0.38) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL425714 | 0.77 | CYP2A6 (0.46) | — | |
| SCHEMBL427975 | 0.76 | CYP11B1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | GRM5 958/4885MAP3K14 4012/4885HAO1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.